The pharmaceutical industry is on the brink of a radical transformation, primarily catalyzed by the integration of artificial intelligence (AI) in drug research and development (R&D). Sanofi, a major player in the sector, embodies this trend by optimizing drug target discovery through AI. Simultaneously, strategic collaborations, such as the one between Pfizer and an Austrian institute, aim to develop innovative AI models. However, these advances come with regulatory and ethical challenges, necessitating a rapid adaptation of legislative frameworks.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
